• IceCure Medical completed the first patient treatment in its ChoICE post-marketing study evaluating ProSense cryoablation for low-risk breast cancer.
• The patient was treated at West Cancer Center & Research Institute in Germantown, Tennessee.
• The study targets approximately 400 patients across up to 30 U.S. sites, evaluating ProSense within its FDA-cleared indication.
• Participating centers are expected to offer commercial treatment to eligible patients outside the study, expanding access to ProSense.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610270833PR_NEWS_USPR_____IO82028) on October 27, 2026, and is solely responsible for the information contained therein.